Studying a cohort of AML patients receiving histamine dihydrochloride and low dose interleukin (IL)-2 to prevent relapse, Hallner et al. found that patients carrying at least one −21M HLA-B had a better clinical outcome [29]. This evidence concerns the gene IL2 and acute myeloid leukemia.